The Masters haven't mentioned Onyx Pharmaceuticals Inc (NASDAQ:ONXX) in a long time, since our 100%+ gain with our Master Picks Newsletter.  Barron's is jumping on the bandwagon now that shares are down to $33.  Can Nexavar, Onyx's cancer drug take the company and stock back into the spotlight? Onyx Pharmaceuticals Inc's (NASDAQ:ONXX) cancer drug has bright potential in treating several forms of the disease and could raise the biotech company's shares, according to a report on Sunday in Barron's (Paid portion only, thus no link provided). With sales of its drug Nexavar, now approved to treat kidney and liver cancer, expected to hit $1 billion next year, Barron's said one health-care investor is looking for earnings of $1.93 per share, and valuing the stock at $65 to $75 per share....